LAURA SZAKAL: Open Payments
NPI 1710119904 · FLINT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,274 in 100 payments from 21 companies in 2025. Trend: 2023 $2,180 · 2024 $3,026 · 2025 $2,274
Food & beverage: $2,179Education: $95
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 18 | $343 |
| Novartis Pharmaceuticals Corporation | 10 | $298 |
| Amgen Inc. | 18 | $192 |
| ABIOMED | 4 | $185 |
| Alnylam Pharmaceuticals Inc. | 8 | $185 |
| Actelion Pharmaceuticals US, Inc. | 4 | $177 |
| Merck Sharp & Dohme LLC | 7 | $176 |
| PFIZER INC. | 6 | $137 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $120 |
| AstraZeneca Pharmaceuticals LP | 5 | $94 |
Products named: LEQVIO, JOT DX, REPATHA, VERQUVO, OPSUMIT, ONPATTRO, Kerendia, ELIQUIS.
Industry payments across MI — which companies pay providers there.
